Post-earnings recap
Reported
Tue, Aug 8, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Cytek Biosciences reported a loss per share of $0.03, which was below expectations. The stock reacted negatively, declining by 2.73%. The lack of revenue figures and management commentary leaves investors with limited insights into the company's performance and future outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.03 | N/A | -1100.00% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.